Health-Related Quality of Life in Patients with Metastatic Basal Cell Carcinoma Treated with Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial

Main Article Content

Karl D Lewis
Timothy J Inocencio
Ruben GW Quek
Patrick R LaFontaine
Zeynep Eroglu
Anne Lynn S Chang
Cristina Ivanescu
Alexander J Stratigos
Ketty Peris
Aleksandar Sekulic
Matthew G Fury
Chieh-I Chen

Keywords

quality of life, cemiplimab, metastatic basal cell carcinoma, open-label, Phase 2

References

1. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

2. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. Libtayo® [cemiplimab-rwlc injection for intravenous use] prescribing information. Revised November 2022. Available at: https://www.regeneron.com/downloads/libtayo_fpi.pdf. Accessed January 30, 2023.

3. Lewis K et al. Cancer Res. 2022;82(12 suppl):CT165.

4. Stratigos AJ et al. J Clin Oncol. 2021;39(15 suppl):9566.

5. Stratigos AJ et al. Lancet Oncol. 2021;22:848–857.

6. Aaronson NK et al. J Natl Cancer Inst. 1993;85:365–376.

7. Chren MM et al. J Cutan Med Surg. 2001;5:105–110.

8. Osoba D et al. J Clin Oncol. 1998;16:139–144.

9. Hansson J et al. Eur J Dermatol. 2018;28:775–783.

10. Scott NW et al. EORTC QLQ-C30 Reference Values. Available at: https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf. Accessed January 30, 2023.

Article Sidebar

PDF
Published
Jan 16, 2024
DOI https://doi.org/10.25251/skin.8.supp.337

Article Details

How to Cite
Lewis, K. D., Inocencio, T. J., Quek, R. G., LaFontaine, P. R., Eroglu, Z., Chang, A. L. S., Ivanescu, C., Stratigos, A. J., Peris, K., Sekulic, A., Fury, M. G., & Chen, C.-I. (2024). Health-Related Quality of Life in Patients with Metastatic Basal Cell Carcinoma Treated with Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial. SKIN The Journal of Cutaneous Medicine, 8(1), s337. https://doi.org/10.25251/skin.8.supp.337
Issue
Vol. 8 No. 1 (2024): January 2024 Issue
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>